Vasospasm Clinical Trial
Official title:
Targeting Carbonic Anhydrase Mediated Coupling as a Novel Vasospasm Prophylaxis in Aneurysmal Sub Arachnoid Hemorrhage
Subarachnoid Hemorrhage (SAH) can occur commonly in the setting of trauma or brain aneurysm.
SAH accounts for 10% of all the strokes. Aneurysmal SAH accounts for 80 % of cases of
non-traumatic cases of SAH, 6-8% of all strokes and 22-25% of all cerebrovascular deaths.
Mortality can be 50% in the first few years of aneurysmal SAH rupture, 15% are severely
disabled post SAH and only 20-35% having a moderate to good recovery it has gained lot of
attention and pre-clinical and clinical trials of various agents have been tried to prevent
poor outcome. The United States epidemiology data reveals the fact that 1% to 5% of adults
have unruptured brain aneurysm and 30,000 people suffer from aneurysm rupture annually
translating to brain aneurysm rupture every 18 minutes.
Vasospasm is the most common SAH complication post 24 hours. It is the segmental or diffuse
narrowing of the vessels especially the large vessels. Fifty percent of those patients who
develop clinical vasospasm, progress to infarction and 15-20% will advance to disabling
stroke or die of cerebral ischemia. The present treatment modalities are insufficient to
prevent vasospasm. So, we need new treatment modalities to decrease the mortality and
morbidity in SAH patients.
The investigators hypothesize that Acetazolamide administration can prevent development of
vasospasm after aneurysmal SAH.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | September 2015 |
Est. primary completion date | September 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: 1. All aneurysmal SAH patients with clinical and or radiological diagnosis. 2. Subjects with age =18 years and =80 years at the time of screening. 3. The subject or his/ her legal representative is willing to undergo informed consent process prior to enrollment into this study. 4. World Federation of Neurosurgeons scale score = 2 5. Hunt and Hess Stroke scale score = 2 6. Mean velocities of < 200 cm/s in at least 1 vascular axis of the circle of Willis 7. Patients admitted within 4 days of symptom onset. Exclusion Criteria: 1. Subject with age < 18 years and >80 years at the time of screening. 2. Time of symptom onset cannot be determined. 3. Subject who is pregnant or lactating. 4. Subjects who have hypersensitivity to acetazolamide, sulfa drugs, or any component of the formulation. 5. Mean velocities of = 200 cm/s in at least 1 vascular axis of the circle of Willis 6. Brain CT or MRI show acute infarction 7. Any acute focal neurological deficit (including any one of these) speech problems, loss of vision, facial or extremity weakness. 8. Hunt and Hess Stroke scale scores > 2 9. World Federation of Neurosurgeons scale scores > 2 10. Subjects with hepatic disease or insufficiency or cirrhosis. 11. Subjects with severe renal disease or dysfunction. 12. Subjects who have decreased sodium and/or potassium levels; hyperchloremic acidosis. 13. Subjects who have adrenocortical insufficiency. 14. The subject or legal representative is unable to provide informed consent. 15. The subject is medically unstable to participate in the trial as determined by the principal investigator. 16. The subject has any end stage medical condition as determined by the principal investigator. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Florida |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Modified Rankin Score | The modified Rankin Scale (m-RS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people after they have suffered a stroke including subarachnoid hemorrhage. The score is given according to following scale. 0- No symptoms at all No significant disability despite symptoms; able to carry out all usual duties and activities Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance Moderate disability; requiring some help, but able to walk without assistance Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance Severe disability; bedridden, incontinent and requiring constant nursing care and attention Dead |
At 3 months from the baseline | Yes |
Primary | Neurological examination of the subject | Neurological status of a subject is assessed by physical neurological examination of the subject by a qualified neurologist. It is one of the most important aspect in determining neurological health of a subject after subarachnoid hemorrhage. It also helps to determine subarachnoid hemorrhage severity and prognosis. | Baseline, 10 days, 3 months | Yes |
Primary | Glasgow Outcome Score | The Glasgow Outcome Scale (GOS) was developed to rank outcomes after head injury, but has been used in stroke studies including subarachnoid hemorrhage. The score is given according to following scale ranging from 1-5. Death- Severe injury or death without recovery of consciousness Persistent vegetative state- Severe damage with prolonged state of unresponsiveness and a lack of higher mental functions Severe disability- Severe injury with permanent need for help with daily living Moderate disability- No need for assistance in everyday life, employment is possible but may require special equipment. Low disability- Light damage with minor neurological and psychological deficits. |
At 3 months from the baseline | Yes |
Primary | Hunt and Hess Scale | The Hunt and Hess scale, is one of the grading systems used to classify the severity of a subarachnoid hemorrhage based on the patient's clinical condition. It is used as a predictor of patient's prognosis/outcome, with a higher grade correlating to lower survival rate. It gives an index of the mortality associated with the various grades. The mortality is minimum with grade 1 and maximum with grade 5. The grades are as follows: Asymptomatic, mild headache, slight nuchal rigidity Moderate to severe headache, nuchal rigidity, no neurologic deficit other than cranial nerve palsy Drowsiness / confusion, mild focal neurologic deficit Stupor, moderate-severe hemiparesis Coma, decerebrate posturing |
Baseline, 10 days | Yes |
Primary | World Federation of Neurosurgeons Scale | The World Federation of Neurosurgeons (WFNS) classification uses Glasgow coma score (GCS) and focal neurological deficit to gauge severity of symptoms. It is intended to be a simple, reliable and clinically valid way to grade a patient with subarachnoid hemorrhage. The prognosis becomes worse when we move from grade 1 to grade 5. Grade 1 represents a GCS of 15 with absent focal neurological deficit, Grade 2 represents a GCS of 13-14 with absent focal neurological deficit, Grade 3 represents a GCS of 13-14 with focal neurological deficit present, Grade 4 represents a GCS of 7-12 with present or absent focal neurological deficit, Grade 5 represents a GCS of <7 with present or absent focal neurological deficit. |
Baseline, 10 days | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06073145 -
Transcranial Doppler Using Wearable Ultrasound Patch
|
||
Active, not recruiting |
NCT01752946 -
A Registry Study of Shuxuening Injection Used in Hospitals in China
|
N/A | |
Completed |
NCT00282893 -
Balloon Prophylaxis of Aneurysmal Vasospasm
|
Phase 2 | |
Completed |
NCT02351518 -
Cerebral Autoregulation and Vasospasm in Patients With TBI
|
||
Terminated |
NCT02071875 -
Comparing the Nautilus NeuroWaveTM to TCD or DSA for the Detection of Vasospasm
|
||
Completed |
NCT00968227 -
Effect of Red Blood Cell Transfusion on Brain Metabolism in Patients With Subarachnoid Hemorrhage
|
Phase 1/Phase 2 | |
Recruiting |
NCT05628948 -
Vascular Lab Resource (VLR) Biorepository
|
||
Recruiting |
NCT06329635 -
Treatment of Vasospasm of Aneurysmal Subarachnoid Hemorrhage With Intrathecal Nicardipine - FAST-IT Trial
|
N/A | |
Completed |
NCT04988932 -
Inhaled Nitric Oxide Treatment for Aneurysmal SAH Patients With Intractable Cerebral Vasospasm
|
N/A | |
Terminated |
NCT02222727 -
Effects of Donepezil on Regional Cerebral Blood Flow Following Aneurysmal Subarachnoid Haemorrhage
|
Phase 2 | |
Completed |
NCT01779713 -
Transcriptomic Signature of Vasospasm Consecutive to Sub-arachnoid Aneurismal Hemorrhage
|
||
Active, not recruiting |
NCT04998370 -
Cerebrospinal Fluid Hemoglobin to Monitor for Aneurysmal Subarachnoid Hemorrhage Related Secondary Brain Injury
|
||
Recruiting |
NCT04362527 -
Milrinone Infusion for VAsospam Treatment in Subarachnoid hemoRrhage
|
Phase 3 | |
Terminated |
NCT00930072 -
Safety Study of Cervical Sympathetic Block for Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage
|
Phase 2 | |
Completed |
NCT03894904 -
Papaverine vs Heparin for Peripheral Arterial Catheter Patency in Pediatric Patients
|
Phase 4 | |
Withdrawn |
NCT02093182 -
An Innovative Non-invasive Acoustic Approach to Detect and Monitor Cerebral Vasospasm
|
N/A |